Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review presents evidence supporting acupuncture's potential benefits for AA treatment but notes the findings are limited by low-quality evidence and small sample sizes, suggesting a need for future large-scale, rigorous studies.

This study observed that men with early-onset androgenetic alopecia had increased carotid intima-media thickness and insulin resistance, suggesting a potential link to premature atherosclerosis.

In this study, researchers investigated the effects of Aqueous Artocarpus heterophyllus seed extract on testosterone enanthate-induced benign prostatic hyperplasia in adult Wistar rats, using three different dosages to assess its potential as an alternative therapy. Results are not reported in this abstract.

This article reviews the role of the National Alopecia Areata Foundation in promoting research and collaboration to find treatments or a cure for alopecia areata and reports no clinical results.

This lecture abstract discusses a career driven by a commitment to helping patients with vitiligo and hidradenitis suppurativa but reports no scientific findings.

This abstract contains only supplementary material information and reports no new research findings.

This letter discusses the use of UVA-1 in the treatment of alopecia areata but reports no new clinical results.

In this study, four months of twice-daily application of A100 gel significantly increased hair growth in men with androgenic alopecia, with no reported side effects.

This review reports that alopecia areata negatively affects sexual functioning, highlighting the need for further research due to limitations in current study sizes and populations.

This review discusses the National Alopecia Areata Foundation's efforts to evaluate and advance alopecia areata research, focusing on immunology and drug development, and reports no new clinical results.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This case report describes the treatment of a 12-year-old female with Alopecia Areata using oral azathioprine.

In this research, the authors reported that long-term treatment with the JAK1/JAK2 inhibitor baricitinib effectively maintains hair regrowth in patients with severe alopecia areata and may gradually improve outcomes for partial responders over 104 weeks, without increasing side effect incidence.

This review discusses squaric acid dibutylester's use, effects, and safety in treating alopecia areata, but reports no new clinical results.

This study found that all-trans-retinoic acid (ATRA) inhibits mink hair follicle growth by reducing dermal papilla cell proliferation and inducing apoptosis, likely through the TGF-β2/Smad2/3 pathway.

This study found that a novel nano-engineered platform, PCA, significantly promoted hair regeneration in an androgenetic alopecia mouse model by enhancing angiogenesis and hair follicle stem cell proliferation, showing promise for future hair regrowth treatments.

Patients and doctors often disagree on alopecia areata severity and treatment satisfaction.

This review discusses the evaluation, diagnosis, and management of beard alopecia areata and reports no new clinical results, though it highlights recent treatment advances with janus kinase inhibitors.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This study found that the STRIAA scoring tool provides a rapid and highly reliable assessment of alopecia areata severity, showing a significant correlation with the traditional SALT score, thus enhancing clinical evaluation in patients with this condition.

This case study reported that a 24-year-old patient with severe, treatment-resistant alopecia areata experienced excellent clinical improvement after one month of treatment with tofacitinib, a JAK inhibitor.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

This study found that phototoxic psoralen and ultraviolet A therapy with topical 8-MOP was effective in treating alopecia areata resistant to other treatments, improving hair regrowth with minimal side effects.

This study found that adding allergen immunotherapy to conventional treatment may reduce relapse-related hair loss in house dust mite-allergic alopecia areata patients over a 3-year period.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

This study suggests that macrophages, especially CD206+ subsets, play a key role in hair growth induced by squaric acid dibutyl ester, a therapy used for alopecia areata.

This vodcast discusses various tools for assessing the severity of alopecia areata, emphasizing the importance of considering psychosocial impacts alongside physical symptoms.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This study found that the Alopecia Areata Symptom Impact Scale (AASIS) is a better tool than the Alopecia Areata Quality of Life Index (AA-QLI) for assessing patient-reported outcomes in alopecia areata.